Intellia Therapeutics (NTLA) reported a Q4 net loss Thursday of $1.27 per diluted share, narrower than a loss of $1.46 a year earlier.
Analysts polled by FactSet expected a loss of $1.33.
Collaboration revenue for the quarter ended Dec. 31 was $12.9 million, compared with a revenue loss of $1.9 million a year earlier.
Analysts surveyed by FactSet expected $8.6 million.
The company said it had cash, cash equivalents and marketable securities of $861.7 million as of Dec. 31, which is expected to fund operations into H1 2027.
Intellia shares were rising past 5% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.